OncoPharm

• Acalabrutinb + BR and sotorasib + panitumumab

  FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

  --------  

  8:47
• Datoptamab deruxtecan

  Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.

  --------  

  18:49
• Dex Dosing in MM, Tec-Tal, & postMONARCH

  HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBR Dexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939 Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939 postMONARCH: https://doi.org/10.1200/JCO-24-02086

  --------  

  12:17
• Breakwater, Ensartinib, & SC Nivo

  We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

  --------  

  10:52
• The Accelerated Approval Pathway

  Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer. Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5

  --------  

  13:14

Więcej Nauka podcastów

Trendy w podcaście Nauka

O OncoPharm